UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009622
Receipt number R000003874
Scientific Title Prospective multicenter trial on the identification of novel biomarkers for Sunitinib therapy in the treatment of Japanese patients with metastatic renal cell carcinoma
Date of disclosure of the study information 2012/12/25
Last modified on 2012/12/25 14:56:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective multicenter trial on the identification of novel biomarkers for Sunitinib therapy in the treatment of Japanese patients with metastatic renal cell carcinoma

Acronym

Prospective multicenter trial on the identification of novel biomarkers for Sunitinib therapy in the treatment of metastatic renal cell carcinoma

Scientific Title

Prospective multicenter trial on the identification of novel biomarkers for Sunitinib therapy in the treatment of Japanese patients with metastatic renal cell carcinoma

Scientific Title:Acronym

Prospective multicenter trial on the identification of novel biomarkers for Sunitinib therapy in the treatment of metastatic renal cell carcinoma

Region

Japan


Condition

Condition

renal cell carcinoma

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Exploration of novel biomarkers for response to Sunitinib therapy in the treatment of metastatic renal cell carcinoma in Japanese patients

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

inflammation markers
IL-6, CRP, IL-8, hepcidin
immunologic markers
Th1/Th2 bias, TReg, MDSC
angiogenesis markers
VEGF-C, soluble VEGFR-2, soluble VEGFR-3, b-FGF

Key secondary outcomes

response rate, progression free survival, overall survival, safety


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Japanese patients older than 18.
2.Diagnosed as metastatic renal cell carcinoma with clear cell component.
3.No chemotherapy/radiation has been performed/ or No efficacy by cytokine treatment
4.Having evaluable disease by CT scan, which is regulated in RECIST.
5. Performance status (ECOG) 0-1
6. Maintaining vital organ functions
7. Survival period is expected more than 12 weeks
8. Informed consent has been obtained

Key exclusion criteria

1.brain metastasis
2.uncontrollable hypertention
3.Active or symptomatic angina pectoris or coronary artery disease (myocardial infarction within 12 months or symptomatic unstable angina), Symptomatic congestive heart failure, Long QTc
4.History of being allergic to Sunitinib
5.Pregnant or lactating woman, including the possibility of pregnant
6.Post organ transplantation, including hematopoietic stem cell transplantation
7.History of malignancy, excluding following cases
Cervical cancer (carcinoma in situ), Basal cell carcinoma, Superficial bladder cancer(Ta, Tis and T1, which have been treated properly
Malignancies treated radically more than 3 years before, without recurrence
8.History of VEGF/ VEGF-R targeted therapy
9.Systemic treatment with steroids
10.Interstitial pneumonia

Target sample size

70


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Mototsugu Oya

Organization

Keio University School of Medicine

Division name

Department of Urology

Zip code


Address

35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan

TEL

03-5363-3825

Email



Public contact

Name of contact person

1st name
Middle name
Last name Ryuichi Mizuno

Organization

Keio University School of Medicine

Division name

Department of Urology

Zip code


Address

35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan

TEL

03-5363-3825

Homepage URL


Email

mizunor@z7.keio.jp


Sponsor or person

Institute

Tokyo metropolitan Sutent study group

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

慶應義塾大学病院、日本医科大学付属病院、東京慈恵会医科大学付属病院、東京慈恵会医科大学付属柏病院、杏林大学医学部付属病院、東京女子医科大学付属病院、埼玉医科大学付属病院、川崎市立川崎病院、


Other administrative information

Date of disclosure of the study information

2012 Year 12 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2009 Year 08 Month 28 Day

Date of IRB


Anticipated trial start date

2009 Year 11 Month 01 Day

Last follow-up date

2011 Year 12 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Changes in biomarkers for response to Sunitinib therapy


Management information

Registered date

2012 Year 12 Month 25 Day

Last modified on

2012 Year 12 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003874


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name